What are the side effects of Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend?

Side effects documented in research include: Individual component side effects apply; Water retention from GH component; Injection site reactions. For educational reference only.

Peptide Blends

Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend

A research blend combining Fragment 176-191 with Mod GRF 1-29 and ipamorelin — identical in design to the CJC-1295 + Ipamorelin + Fragment blend but labeled under the Mod GRF 1-29 nomenclature.

Multiple componentsHalf-life: Fragment 176-191: ~1 hour; Mod GRF: ~30-60 min; Ipamorelin: ~2 hours

Community Rating

No ratings yet

Compound Profile

Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend

Key Data

FormulaMultiple components

Half-lifeFragment 176-191: ~1 hour; Mod GRF: ~30-60 min; Ipamorelin: ~2 hours

CategoryPeptide Blends

Research reference only

Research Focus

Same design as Fragment 176-191 + CJC-1295 + Ipamorelin

Selective lipolysis + GH axis stimulation

Combined fat loss + lean mass support

Preclinical data

⚠ Research & Educational Use Only. Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.

Chemistry review: Ashish KumarWritten by the KnowYourPeptide Research TeamLast updated August 2026

Our editorial standards →

Key Takeaways

Same design as Fragment 176-191 + CJC-1295 + Ipamorelin
Selective lipolysis + GH axis stimulation
Combined fat loss + lean mass support
Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.

Research At a Glance

Same design as Fragment 176-191 + CJC-1295 + Ipamorelin
Selective lipolysis + GH axis stimulation
Combined fat loss + lean mass support
Physiological GH pulsatility preserved

Calculate Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend dose

Who researches this:Researchers preferring pulsatile GH protocols over sustained elevation for fat reduction researchThose comparing pulsatile (Mod GRF) vs sustained (CJC-1295-DAC) GH combinations alongside Fragment 176-191People studying the fat mobilization profile of short-acting GHRH + GHRP + lipolytic fragmentScientists investigating whether pulsatile GH pattern changes the fat reduction outcome of fragment protocols

💡

In Plain English

Simple summary

Fragment 176-191 + Mod GRF 1-29 + Ipamorelin is the pulsatile version of the fat-reduction GH secretagogue combination -- using short-acting Mod GRF (30-minute half-life) instead of long-acting CJC-1295-DAC alongside the lipolytic fragment. This variant produces sharp, discrete GH pulses alongside the fragment's direct lipolytic activity, as opposed to the sustained GH elevation of the CJC-1295-DAC version. Researchers who prefer the pulsatile GH pattern for physiological mimicry choose this combination for fat reduction protocols.

Same design as Fragment 176-191 + CJC-1295 + Ipamorelin
Selective lipolysis + GH axis stimulation
Combined fat loss + lean mass support

The full scientific detail, mechanisms, citations, and dosing data, follows below.

What is Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend?

Tap any underlined term for an instant definition.

Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend is functionally identical to the Fragment 176-191 + CJC-1295 + Ipamorelin blend. The naming difference reflects that CJC-1295 (without DAC) and Mod GRF 1-29 are the same compound; researchers and suppliers sometimes use one name, sometimes the other.

What It Is

Same three-component design: Fragment 176-191 (selective lipolysis) + Mod GRF 1-29 / CJC-1295 no DAC (GHRHR) + Ipamorelin (GHS-R1a)
Mechanism, expected outcomes, and dosing identical to Fragment 176-191 + CJC-1295 + Ipamorelin blend

Mechanism

Fragment 176-191: beta-adrenergic receptor-like agonism on adipocytes; reduces fat mass without affecting IGF-1
Mod GRF 1-29 + Ipamorelin: synergistic GHRHR + GHS-R1a stimulation producing 3-4x GH pulses vs either alone

Dosing From the Literature

Fragment 176-191: 200-500 mcg subcutaneous, morning fasted
Mod GRF 1-29: 100-200 mcg per injection
Ipamorelin: 200-300 mcg per injection
Combined in single administration

Storage and Handling

Lyophilised: 2-8 degrees C; 24 months
Reconstituted: 2-8 degrees C; use within 21 days

By the Numbers

Pulsatile GH + direct lipolysis

Short-acting Mod GRF creates natural-pattern GH pulses; Fragment 176-191 provides direct, GH-independent fat mobilization

Multiple daily injections

All three components need dosing 1-3x daily -- higher injection frequency than CJC-1295-DAC alternatives

Fat-focused triple combination

Designed specifically for fat reduction research -- the fragment targets fat directly; the GH secretagogues target it indirectly

Key Research Benefits

Documented effects observed in preclinical and clinical studies on Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend. See all Peptide Blends peptides for comparison.

Same design as Fragment 176-191 + CJC-1295 + Ipamorelin

Selective lipolysis + GH axis stimulation

Combined fat loss + lean mass support

Physiological GH pulsatility preserved

Side Effects & Risks

Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →

Dosing Data from the Literature

Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.

Research Dosing Protocol

Fragment 176-191 200-500 mcg + Mod GRF 1-29 100-200 mcg + Ipamorelin 200-300 mcg per injection.

Enter your vial size and target dose to get the exact injection volume.

Administration in Research Settings

Standard reconstitution and administration methodology for laboratory research use.

Subcutaneous injection. Administer fasted in the morning for optimal fat mobilization.

What the research doesn't show

The combination-specific human data for this three-compound protocol doesn't exist in published literature. Protocols combining three separate research peptides require careful dose adjustment to avoid overlap effects. The injection frequency required with short-acting Mod GRF is a practical barrier that leads many researchers to use the CJC-1295-DAC version despite its less physiological GH profile.

Medical Expert Videos

Physicians, researchers, and pharmacologists explain Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend, covering mechanisms of action, clinical context, and study findings.

YouTube, Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend · doctors & researchersOpen in YouTube

Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.

📋

The Bottom Line

Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: same design as fragment 176-191 + cjc-1295 + ipamorelin.

The most commonly reported side effect in research subjects is individual component side effects apply. It is a research chemical, not approved for human use.

Research chemicalNot for human useEducational purposes only

Frequently Asked Questions

Explore Further

All Peptide Blends research peptides Full research peptide directory Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend dose calculator Compare Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend with other peptides Browse all research categories Full site index

Quick Reference

More in Peptide Blends

View all in category

How It Compares

Fragment 176-191 + CJC-1295 + Ipamorelin is the sustained-GH version of the same combination strategy. Mod GRF version requires more frequent injections for the same GH axis coverage. Whether the pulsatile vs sustained GH pattern meaningfully changes fat reduction outcomes in practice is an open research question.

Compare Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend side-by-side

Research Use Only

This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.